Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionExchange Traded Concepts, Llc
Latest Disclosed Ownership3,252 shares
Latest Disclosed Value $ 1,075,989
Exchange Traded Concepts, Llc reports 37.74% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 15, 2026 - Exchange Traded Concepts, Llc filed a 13F-HR form disclosing ownership of 3,252 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $929,096 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 14, 2026 disclosing 2,361 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 37.74% during the quarter. The current value of the position is $847,146 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,252 891 37.74 1,076 14.61 0.0037
2026-01-14 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,361 288 13.89 939 -0.74 0.0071
2025-10-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,073 -733 -26.12 945 3.28 0.0080
2025-07-10 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,806 -909 -24.47 915 -8.77 0.0112
2025-04-17 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,715 -118 -3.08 1,003 11.32 0.0172
2025-01-21 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,833 265 7.43 902 -8.15 0.0179
2024-10-10 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,568 136 3.96 981 17.77 0.0229
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,432 -356 -9.40 834 47.17 0.0211
2024-04-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,788 -1,625 -30.02 566 -45.37 0.0146
2024-01-05 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,413 2,040 60.48 1,036 73.53 0.0277
2023-10-18 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,373 -4,860 -59.03 597 -61.80 0.0169
2023-07-20 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,233 -13,035 -61.29 1,564 -63.31 0.0385
2023-04-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,268 13,900 188.65 4,260 143.29 0.1167
2023-01-27 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 7,368 -724 -8.95 1,751 8.09 0.0502
2023-01-18 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,368 -724 2 0.0502
2022-10-07 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,092 -5,161 -38.94 1,620 -16.19 0.0530
2022-07-20 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,253 -279 -2.06 1,933 -12.53 0.0562
2022-04-26 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,532 4,618 51.81 2,210 46.16 0.0443
2022-01-13 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,914 -177 -1.95 1,512 -11.89 0.0293
2021-10-18 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,091 -1,997 -18.01 1,716 -8.72 0.0438
2021-07-30 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,088 344 3.20 1,880 23.93 0.0595
2021-04-20 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,744 3,368 45.66 1,517 58.19 0.0568
2021-01-19 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,376 4,629 168.51 959 139.75 0.0445
2020-10-30 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,747 1,272 86.24 400 83.49 0.0226
2020-07-15 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,475 768 108.63 218 183.12 0.0362
2020-04-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 707 323 84.11 77 75.00 0.0416
2020-01-22 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 384 384 44 0.0092
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.